Mineralys Therapeutics (MLYS) Assets Average (2023 - 2026)

Mineralys Therapeutics (MLYS) has 4 years of Assets Average data on file, last reported at $657.3 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 134.41% year-over-year to $657.3 million; the trailing twelve-month figure through Mar 2026 stood at $657.3 million (up 134.41% YoY), and the FY2025 full-year result was $433.9 million, up 89.65% from the prior year.
• Assets Average rose to $657.3 million in Q1 2026, from $630.9 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $657.3 million in Q1 2026 to a low of $210.4 million in Q1 2023.
• A 4-year average of $354.1 million and a median of $298.8 million in 2023 frame the typical range for Assets Average.
• Across the five-year window, Assets Average dropped 10.4% in 2024 and soared 166.11% in 2025, its largest moves.
• Tracing MLYS's Assets Average over 4 years: stood at $264.6 million in 2023, then slipped by 10.4% to $237.1 million in 2024, then soared by 166.11% to $630.9 million in 2025, then rose by 4.19% to $657.3 million in 2026.
• Business Quant data shows MLYS's Assets Average at $657.3 million in Q1 2026, $630.9 million in Q4 2025, and $467.8 million in Q3 2025.